ClinicalTrials.gg
CompletedNCT00571584Updated Jan 12, 2017

High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors

A Phase 4 interventional study of activated recombinant human factor VII in Congenital Bleeding Disorder, Haemophilia A With Inhibitors and Haemophilia B With Inhibitors, sponsored by Novo Nordisk A/S. Completed at 18 sites in 7 countries. Open to male participants. Per ClinicalTrials.gov, last updated 2017-01-12.

Sponsored by Novo Nordisk A/S · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
24
Allocation
Randomized
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing recombinant FVIIa in Hemophilia A — 1 open to participants now, 1 under way, none of them phase 3. recombinant FVIIa · Hemophilia A.

Enrollment
10th of 19
24 · median 24
Started
2002
with 1 other
Phase 4
4 of 20
1 open now
Registered
6th of 20
by date
Lead sponsor
11 of 20
Novo Nordisk A/S

Among the 20 studies testing recombinant FVIIa in Hemophilia A, this one is the 10th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2002, is one of 4 in phase 4, and was the 6th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 20 studies testing recombinant FVIIa in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About recombinant FVIIa

recombinant FVIIa: first FDA approval 1999 (Novoseven, Novoseven Rt), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing recombinant FVIIa in Hemophilia A, or all of them as a file.
02

Study summary

This trial is conducted in Europe. The aim of this trial is to evaluate the efficacy and safety of two dose schedules of activated recombinant human factor VII in treatment of joint bleeds in haemophilia patients with inhibitors.

03

Conditions studied

  • Congenital Bleeding Disorder
  • Haemophilia A With Inhibitors
  • Haemophilia B With Inhibitors
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosed of congenital haemophilia A or B with inhibitors to factor VIII or IX, respectively
  • A history of 3 or more joint bleeds during the last 12 months

Exclusion criteria

Exclusion Criteria:

  • Joint bleeding within 7 days prior to trial start
  • Treatment for bleeds within the last 5 days prior to trial start
  • coagulation disorders other than congenital haemophilia A or B
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)
06

What researchers measure

Primary outcomes

  1. Global treatment response of the patient by an algorithm based pain and joint mobility assessments

Secondary outcomes

  1. Pain assessment

  2. Mobility assessment

  3. Circumference of joint

  4. Adverse events

07

Study locations

18 sites
  • Novo Nordisk Investigational Site
    Kremlin-Bicêtre, 94270, France
  • Novo Nordisk Investigational Site
    Lille, 59037, France
  • Novo Nordisk Investigational Site
    Lyon, 69003, France
  • Novo Nordisk Investigational Site
    Paris, 75014, France
  • Novo Nordisk Investigational Site
    Paris, 75015, France
  • Novo Nordisk Investigational Site
    Budapest, 1135, Hungary
  • Novo Nordisk Investigational Site
    Tel-Hashomer, 52621, Israel
  • Novo Nordisk Investigational Site
    Poznan, 61-833, Poland
  • Novo Nordisk Investigational Site
    Warszawa, 00-576, Poland
  • Novo Nordisk Investigational Site
    Warszawa, 00-791, Poland
  • Novo Nordisk Investigational Site
    Wroclaw, 50-345, Poland
  • Novo Nordisk Investigational Site
    Madrid, 28046, Spain
  • Novo Nordisk Investigational Site
    Valencia, 46026, Spain
  • Novo Nordisk Investigational Site
    Bornova-IZMIR, 35100, Turkey
  • Novo Nordisk Investigational Site
    Capa-ISTANBUL, 35100, Turkey
  • Novo Nordisk Investigational Site
    Birmingham, B15 2TH, United Kingdom
  • Novo Nordisk Investigational Site
    Canterbury, United Kingdom
  • Novo Nordisk Investigational Site
    Sheffield, S10 2JF, United Kingdom
08

References and documents

Publications

  • Kavakli K, Makris M, Zulfikar B, Erhardtsen E, Abrams ZS, Kenet G; NovoSeven trial (F7HAEM-1510) investigators. Home treatment of haemarthroses using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost. 2006 Apr;95(4):600-5. PubMed 16601828 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2002, a primary completion of Mar 2004 and a completion of Mar 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2007
First posted
Dec 12, 2007
Start
Nov 2002
Primary completionActual
Mar 2004
CompletionActual
Mar 2004
Last update
Jan 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00571584
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Dec 12, 2007
Start date
Nov 2002
Primary completion
Mar 2004
Completion
Mar 2004
Last update
Jan 12, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant FVIIa

Start the discussion